Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma

Therapeutics and Clinical Risk Management

Volumn 4, Issue 1, 2008, Pages 205-211

  Goudar, Ranjit K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cisplatin; Malignant pleural mesothelioma; Mesothelioma; Pemetrexed

Indexed keywords

ASBESTOS; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DOXORUBICIN; FOLIC ACID; HOMOCYSTEINE; METHYLMALONIC ACID; PEMETREXED; RALTITREXED;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; GRANULOCYTOPENIA; HUMAN; INCIDENCE; LEUKOPENIA; LUNG CANCER; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PLEURA MESOTHELIOMA; PROGNOSIS; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; REVIEW; SEPSIS; SIDE EFFECT; SURVIVAL TIME; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION;

EID: 41549143873     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Adjei AA, Calvert AH, Hanauske AR, et al. 2000. Pemetrexed (ALIMTA), a novel multitargeted antifolate agent, is active alone and in combination in thoracic tumors. Lung Cancer, 29:38-9.
2. Berghmans T, Paesmans M, Lalami Y, et al. 2002. Activity of chemotherapy and immunotherapy on malignant mesothelioma:a systematic review of the literature with meta-analysis. Lung Cancer, 38:111-21.
3. Boyer M, Jassem J, Al, ALE, 2003. Symptoms and quality of life advantages for pemetrexed + cisplatin versus cisplatin in treatment of malignant pleural mesothelioma. Lung Cancer, 41:S19.
4. British Thoracic Society. 2001. Statement on malignant mesothelioma in the United Kingdom. Thorax, 56:250-65.
5. Budde LS, Hanna NH. 2004. Pemetrexed (Alimta.:improving outcomes in malignant pleural mesothelioma. Expert Rev Anticancer Ther, 4:361-8.
6. Bunn C, Paoletti P, Niyikiza C, et al. 2001. Vitamin B12 and folate reduce toxicity of Alimta™ (pemetrexed disodium, LY231514, MTA., a novel antifolate/antimetabolite. Proc Am Soc Clin Oncol, 20:abstr 300.
7. Ceresoli GL, Zucali PA, Favaretto AG, et al. 2006. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol, 24:1443-8.
8. Curtin NJ, Hughes AN. 2001. Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncol, 2:298-306.
9. Eli lilly and Company. 2004a. Clinical Study Summary:Study H3E-MC-JMAP.
10. Eli Lilly and Company. 2004b. Clinical Study Summary:Study H3E-MC-JMDR.
11. Ellis P, Davies AM, Evans WK, et al. 2006. The use of chemotherapy in patients with advanced malignant pleural mesothelioma:a systematic review and practice guideline. J Thorac Oncol, 1:591-601.
12. Favaretto A. 2005. Overview on ongoing or planned clinical trials in Europe. Lung Cancer, 49(Suppl 1):S117-21.
13. Gatzemeter U. 2004. Pemetrexed in malignant pleural mesothelioma. Oncology (Williston Park), 18:26-31.
14. Gralla RJ, Hollen PJ, Liepa AM, et al. 2003. Improving quality of life in patients with malignant pleural mesothelioma:Results of the randomized pemetrexed + cisplatin vs cisplatin trial using the LCSS-meso instrument. ASCO.
15. Green J, Dundar Y, Dodd S, et al. 2007. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma. Cochrane Database Syst Rev:CD005574.
16. Hazarika M, White RM, Johnson JR, et al. 2004. FDA drug approval summaries:pemetrexed (Alimta). Oncologist, 9:482-8.
17. Hazarika M, White RM Jr, Booth BP, et al. 2005. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res, 11:982-92.
18. Hollen PJ, Gralla RJ, Liepa AM, et al. 2004. Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation. Cancer, 101:587-95.
19. Hughes A, Calvert P, Azzabi A, et al. 2002. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol, 20:3533-44.
20. Manegold C, Symanowski J, Gatzemeier U, et al. 2005. Second-line (post-study. chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol, 16:923-7.
21. Nakagawa K, Kudoh S, Matsui K, et al. 2003. A phase I dose-finding study of pemetrexed supplemented with folic acid (FA. and vitamin B12 in Japanese patients with solid tumors Proc Am Soc Clin Oncol, 22:22.
22. Niyikiza C, Baker SD, Seitz DE, et al. 2002, Homocysteine and methylmalonic acid:markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther, 1:545-52.
23. Paoletti P, Pistolesi M, Rusthoven J, et al. 2003. Correlation of pulmonary function tests with best tumor response status:results from the phase III study of pemetrexed + cisplatin vs cisplatin in malignant pleural mesothelioma. Proc Am Soc Clin Oncol, 22:659.
24. Pearce HL, Alice Miller M. 2005. The evolution of cancer research and drug discovery at Lilly Research Laboratories. Adv Enzyme Regul, 45:229-55.
25. Pistolesi M, Rusthoven J. 2004. Malignant pleural mesothelioma:update, current management, and newer therapeutic strategies. Chest, 126:1318-29.
26. Reck M, Gatzemeier U. 2005. Pemetrexed-cisplatin combination in mesothelioma. Expert Rev Anticancer Ther, 5:231-7.
27. Robinson BW, Lake RA. 2005. Advances in malignant mesothelioma. N Engl J Med, 353:1591-603.
28. Robinson BW, Musk AW, Lake RA. 2005. Malignant mesothelioma. Lancet, 366:397-408.
29. Shepherd FA, Dancey J, Arnold A, et al. 2001. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma:a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer, 92:595-600.
30. Steele JP. 2003. The new front line treatment for malignant pleural mesothelioma? Thorax, 58:96-7.
31. Steele JP, Klabatsa A. 2005. Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol, 16:345-51.
32. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. 1999. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma:results in 183 patients. J Thorac Cardiovasc Surg, 117:54-63; discussion 63-5.
33. Teicher BA, Chen V, Shih C, et al. 2000. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res, 6:1016-23.
34. Thodtmann R, Depenbrock H, Dumez H, et al. 1999. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514. in combination with cisplatin. J Clin Oncol, 17:3009-16.
35. Vogelzang N, Symanowski J, Rusthoven J, et al. 2005. Long-term survival update from the randomized phase III study of pemetrexed plus cisplatin vs. cisplatin in patients with malignant pleural mesothelioma (MPM). Lung Cancer, 49:S230.
36. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. 2003. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol, 21:2636-44.
37. Weill H, Hughes JM, Churg AM. 2004. Changing trends in US mesothelioma incidence. Occup Environ Med, 61:438-41.
38. Zidar BL, Green S, Pierce HI, et al. 1988. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Invest New Drugs, 6:223-6.